OBJECTIVE To devise assays to assess and follow the specific antibody response in patients treated with streptokinase for acute myocardial infarction. DESIGN Venous blood samples were collected before treatment with streptokinase started and subsequently at regular intervals over one year. Specific IgG and subclass IgG1 were assessed by an enzyme linked immunosorbent assay. SETTING Coronary...

BACKGROUND The optimal dose of Streptokinase in the treatment of acute myocardial infarction is not well established. Apparently, the thrombolytic efficacy would not increase with doses over 750,000 units. AIM To compare the effectiveness and safety of treatment with low doses of Streptokinase, ranging from 500,000 to 750,000 units, in patients with ST elevation acute myocardial infarction. ...

BACKGROUND Empyema thoracis in children causes significant morbidity. Standard treatment of Empyema thoracis includes tube drainage and antibiotics. But the tube drainage often fails. Intrapleural Streptokinase has been used in empyema thoracis with good success rate. OBJECTIVES We evaluated the efficacy of intra-pleural Streptokinase in management of empyema thoracis even in advanced stages....

Streptococcus pyogenes (group A streptococcus, GAS) secretes streptokinase, a potent plasminogen activating protein. Among GAS isolates, streptokinase gene sequences (ska) are polymorphic and can be grouped into two distinct sequence clusters (termed cluster type-1 and cluster type-2) with cluster type-2 being further divided into sub-clusters type-2a and type-2b. In this study, far-UV circular...

OBJECTIVE To examine early leucocyte responses and neutrophil activation in acute myocardial infarction treated by streptokinase and to relate the findings to coronary recanalisation and indices of myocardial damage in order to provide further information about the role of neutrophils in the evolution of injury. DESIGN Group analysis of paired blood samples, obtained before streptokinase trea...

BACKGROUND Worldwide, streptokinase remains the most used thrombolytic agent for the treatment of myocardial infarction. Recombinant streptokinase, from E. coli, is increasingly used in developing countries as a biosimilar of native streptokinase; however, potency assignments relative to the WHO International Standard (IS) are highly variable with potentially dangerous consequences. A proportio...

Accepted for publication 13 January 1992 Abstract Objective-To examine the induction of antistreptokinase antibodies after giving streptokinase or anistreplase to patients with acute myocardial infarction. Design-Patients were randomly allocated to receive either 15 x 10' IU, streptokinase or 30U anistreplase in a double blind study. Blood samples were collected immediately before treatment and...

The steady state kinetic parameters of activation of human Gluand Lys-plasminogens and bovine plasminogen by streptokinase and its equimolar complexes with Gluand Lys-plasminogen, Lys-plasmin, and the plasmin-derived light(B) chain, as well as urokinase, were determined. Activation rates were measured at pH 6.0 and 30” by determining the initial velocity of Na-Cbz-L-lysine-p-nitrophenyl ester h...

BACKGROUND The most important complication following cardiac catheterization required urgent therapeutic management is vessel obstruction and arterial thrombosis. The morbidity following this complication can be decreased by surgery intervention and/or thrombolytic drugs. OBJECTIVES In this study we evaluated the effects of ranitidine and hydrocortisone on pediatric patients with congenital h...

Pulmonary edema is rare in patients with pulmonary embolism and to our knowledge has not been described in association with thrombolytic therapy. We describe a patient with massive pulmonary embolism in whom the adult respiratory distress syndrome (ARDS) developed shortly after a course of streptokinase therapy. The possible association between streptokinase therapy or pulmonary embolism and AR...